The Ontario Prescription Opioid Tool allows public access to data related to indicators for opioid prescribing in the province. This update includes data up to December 2018 and a breakdown of pharmacy-dispensed naloxone by type (injectable and intranasal).
High‐strength opioid formulations were delisted (removed) from Ontario’s public drug formulary in January 2017, except for palliative patients. We evaluated the impact of this policy on opioid utilization and dosing.
This study evaluates the impact of the P4P program on fentanyl and non-fentanyl dispensing and opioid-related hospitalizations and deaths.
This study aims to characterize the impacts of policies intended to improve opioid prescribing and prevent opioid-related overdose and death on individuals who take opioids.